REVIEW PAPER
Cancer stem cells – a new chance for successful treatment of cancer
Submission date: 2015-04-17
Final revision date: 2015-06-08
Acceptance date: 2015-06-30
Publication date: 2015-07-13
Medical Studies 2015;31(2):139-145
KEYWORDS
TOPICS
ABSTRACT
Cancer stem cells are undifferentiated cells capable of being transformed into all types of cells comprising the tumour mass. As demonstrated by recent findings, they are responsible for the development of both haematopoietic malignancies and solid lesions. Cancer stem cells determine the unlimited growth of tumours and the variety of their morphology; they are also suspected of being the factor responsible for metastases. Their capability for renewal is the cause of disease recurrences even after long remission periods. Studies have shown that cancer stem cells may develop from normal stem cells, mature cells, and differentiated, or already transformed cells. What differentiate these cells from other cancer cells are rare mitotic divisions, which play a protective role for the cancer genome.
REFERENCES (52)
1.
Gao JX. Cancer stem cells: the lessons from pre-cancerous stem cells. J Cell Mol Med 2008; 12: 67-96.
2.
Ramalho-Santos M, Willenbring H. On the origin of the term “stem cell”. Cell Stem Cell 2007; 1: 35-8.
4.
Bajada S, Mazakova I, Richardson JB, et al. Updates on stem cells and their applications in regenerative medicine. Tissue Eng Regen Med 2008; 2: 169-83.
5.
Ohlstein B, Kai T, Decotto E, et al. The stem cell niche: theme and variations. Curr Opin Cell Biol 2004; 16: 693-9.
6.
Drewa T, Kaźnica A. Stem cells. In: Medical genetics. Elsevier Urban & Partner, Wroclaw 2011.
7.
Bjorson CR, Reitze RL, Reynolds BA, et al. Turning brain into blood: a hematopoetic fate adopted by adult neural stem cells in vivo. Science 1999; 283: 534-7.
8.
Sikorska MA, Olszewski WL. Stem cells – biology and therapeutic use. Adv Exp Med Hig 2004; 58: 202-8.
9.
Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-34.
10.
Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001; 411: 349-54.
11.
Koestenbauer S, Zech NH, Juch H, et al. Embryonic stem cells: similarities and differences between human and murine embryonic stem cells. Am J Reprod Immunol 2006; 55: 169-80.
12.
Kawiak J. Stem cells are the body of an adult in biology and medicine. Adv Cell Biol 2009; 36: 99-110.
13.
Ponnusamy MP, Batra SK. Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res 2008; 1: 1-9.
14.
Preston SL, Alison MR, Forbes SJ, et al. The new stem cell biology: something for everyone. Mol Pathol 2003; 56: 86-96.
15.
Neuzil J, Stantic M, Zabalova R, et al. Tumour-initiating cells vs. cancer ‘stem’ cells and CD133: what’s in the name? Biochem Biophys Res Commun 2007; 355: 855-9.
16.
Parmar K, Mauch P, Vergilio JA, et al. Distribution of hematopoetic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci 2007; 104: 5431-6.
17.
Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med 2007; 85: 1301-7.
18.
Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and role of carbonic anhydrase 9. Cancer Metastasis Rex 2007; 26: 299-310.
19.
Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cell. Blood 2007; 109: 3812-9.
20.
Szala S. Angiogenesis and immunosuppression: yin and yang of cancer progression? Adv Hig Med Exp 2007; 63: 598-612.
21.
Lluis F, Cosma MP. Cell-fusion-mediated somatic-cell reprogramming: a mechanism for tissue regeneration. J Cell Physiol 2010; 223: 6-13.
22.
Ricci-Vitiani L, Lombardi DG, Pilozzi E. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 455: 111-5.
23.
Chybicka A, Sawicz-Birkowska K. Oncology and hematology children. PZWL, Warsaw 2008.
25.
Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003; 10: 159-65.
26.
Orzechowska-Juzwenko K. Outline of cancer chemotherapy and systemic organ. Volumed, Wroclaw 2000.
27.
Scharemberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoetic progenitors. Blood 2002; 99: 507-12.
28.
van der Kolk DM, Vellenga E, Scheffer GL, et al. Expression and activity of breast cancer reststance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 2002; 15: 3763-70.
29.
Jamroziak K, Kowalczyk M, Robak T. Breast cancer resistance protein ABCG2 (BCRP/MXR/ABCP) – A new ABC transporter superfamily associated with multidrug resistance. Acta Haematol Pol 2007; 33: 403-16.
31.
Hombach-Klonisch S, Paranjothy T, Wiechec E, et al. Cancer stem cells as targets for cancer therapy: selected cancers as examples. Arch Immunol Ther Exp 2008; 56: 165-80.
32.
Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26: 2839-45.
33.
Ricci-Vitiani L, Fabrizi E, Palio E, et al. Colon cancer stem cells. J Mol Med 2009; 87: 1097-104.
34.
Takebe N, Ivy SP. Controversies in cancer stem cells: targeting embryonic signaling pathways. Clin Cancer Res 2010;16: 3106-12.
35.
Szaryńska M, Kmieć Z. The role of tumor stem cells in the pathogenesis and therapy of cancer. Family Medicine Forum 2001; 5: 47-56.
36.
Beier D, Hau P, Proescholdt M, et al. CD133+ and CD133– glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-401.
37.
Shipitsin M, Polyak K. The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 2008; 88: 459-63.
38.
Wieczorek K, Niewiarowska J. Cancer stem cells. Progress Hig Med Exp 2012; 66: 629-36.
39.
Statkiewicz M, Małecki M. Stem cancer cells, and tumor resistance to therapy. J Oncol 2009; 59: 456-63.
40.
Femia AP, Dolara P, Salvadori M, et al. Expression of LGR-5, MSI-1 and DCAMKL-1, putative stem cell markers, in the early phases of 1,2-dimethylhydrazine-induced rat colon carcinogenesis: correlation with nuclear beta-catenin. BMC Cancer 2013; 13: 48.
41.
Castellón EA, Valenzuela R, Lillo J, et al. Molecular signature of cancer stem cells isolated from prostate carcinoma and expression of stem markers in different Gleason grades and metastasis. Biol Res 2012; 45: 297-305.
42.
Wu A, Luo W, Zhang Q, et al. Aldehyde dehydrogenase 1, a functional marker for identifying cancer stem cells in human nasopharyngeal carcinoma. Cancer Lett 2013; 330: 181-9.
43.
Yamashita T, Honda M, Nakamoto Y, et al. Discrete nature of EpCAM(+) and CD90(+) cancer stem cells in human hepatocellular carcinoma. Hepathology 2013; 57: 1484-97.
44.
Sathi GA, Tamamura R, Tsujigiwa H, et al. Analysis of immunoexpression of common cancer stem cell markers in ameloblastoma. Exp Ther Med 2012; 3: 397-402.
45.
Matsuda Y, Kure S, Ishiwata T. Nestin and other putative cancer stem cell markers in pancreatic cancer. Med Mol Morphol 2012; 45: 59-65.
46.
Wang C, Xie J, Guo J, et al. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep 2012; 28: 1301-8.
47.
Kawasaki BT, Farrar WL. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun 2007; 364: 778-82.
48.
Lasek W, Malajczyk J. Mechanisms of lymphocyte cytotoxicity. In: Immunology. Gołąb J, Jakóbisiak M, Lasek W, Stokłosa T (eds.). PWN, Warsaw 2007.
49.
Pons J, Huang Y, Takagawa J, et al. Combining angiogenic gene and stem cell therapies for myocardial infarction. J Gene Med 2009; 11: 743-53.
50.
Rozwadowska N, Kurpisz M. Genetic modification of the stem cells for the purpose of ex vivo gene therapy. Adv Cell Biol 2010; 37: 253-69.
51.
Augustyniak J, Sawicki K, Skrzypczak M, Kapka-Skrzypczak L. The use of oncolytic viruses in tumor therapy. Probl Hig Epidemiol 2012; 93: 654-62.
52.
Rahman M, Deleyrolle L, Vedam-Mai V, et al. The cancer stem cell hypothesis: failures and pitfalls. Neurosurgery 2011; 68: 531-45.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
